Lenox Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History
Bought
Maintained
Sold
Other funds holding HZNP
ACA
PC
Lenox Wealth Advisors's HZNP Position: Q1 2022 in Review
Lenox Wealth Advisors reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 11% in Q1 2022, selling an estimated $292 and leaving 24 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #629.
Lenox Wealth Advisors first reported a position in HZNP in Q4 2021 and has held it in 2 quarters since. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.
- Lenox Wealth Advisors held 24 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $3K as of Q1 2022.
- Lenox Wealth Advisors sold 3 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $292.
- Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #629 holding.
- Lenox Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and has held it in 2 quarters since.
- 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.
Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.